Bio-Techne Corporation TECH

Revenue Intelligence Report • 50 quarters of SEC filing data • Updated 2026-03-15

Bio-Techne Corporation has a forecasted full-year revenue of $1.3B, a +7.8% year-over-year change, based on 50 quarters of SEC filing data. Key revenue drivers include SG&A (elasticity 0.41x). The ARDL model achieves strong accuracy at 3.2% MAPE.

Investment Thesis

The econometric model achieves strong accuracy (3.2% MAPE), suggesting Bio-Techne Corporation's revenue trajectory is well-characterized by its spending patterns. Sales & marketing spend shows a 0.41x elasticity, suggesting effective go-to-market execution.

Next FY Revenue
$1.29B
+7.8% YoY
SG&A Elasticity
0.41x
Model Accuracy
3.2% MAPE
Holdout validation: The model predicted $301B vs the actual $296B — an error of 1.6%.
Note: Bio-Techne Corporation does not report R&D expenses separately. This analysis uses SG&A spending only.

Revenue Forecast

TECH Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $301B $296B $278B – $325B +3.9% ✓ In range
Q2 2026 $316B $282B – $353B +6.2%
Q3 2026 $317B $276B – $363B +0.2%
Q4 2026 $321B $275B – $376B +12.1%
Q1 2027 $335B $281B – $399B +13.2%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Bio-Techne Corporation's systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Sep–Nov) 0.986 -1.4% In line with trend 15
FQ2 (Dec–Feb) 1.0072 +0.7% In line with trend 16
FQ3 (Mar–May) 1.0058 +0.6% In line with trend 15
FQ4 (Jun–Aug) 1.0 +0.0% In line with trend 0

How Spending Drives Revenue

TECH Spending Timing
Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

More in Healthcare

CI IDXX PODD GILD COO BIIB INCY JNJ